CLINICAL TRIALS PROFILE FOR CLARINEX D 24 HOUR

All Clinical Trials for clarinex d 24 hour

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00636870 ↗	Fexofenadine (Allegra®) in Healthy Adults Who Have Been Identified as Slow Metabolizers for Desloratadine	Completed	Sanofi	Phase 4	2003-02-01	To evaluate the single-dose and steady-state pharmacokinetics of desloratadine and fexofenadine in desloratadine slow metabolizers. To evaluate the safety and tolerability of desloratadine compared to fexofenadine following single and multiple oral doses administered to desloratadine slow metabolizers.
NCT00637585 ↗	Fexofenadine HCl 180 mg, Desloratadine 5 mg and Placebo in Suppression of Wheal and Flare Induced by Histamine	Completed	Sanofi	Phase 4	2002-12-01	To examine the relative potency, onset of action and duration of action of fexofenadine HCl 180 mg (ALLEGRA) and desloratadine 5 mg (CLARINEX) as compared to placebo on skin wheals and flares induced by histamine.
NCT00757562 ↗	Safety of Desloratadine in Children With Allergy Sensitivity and Chronic Hives, Who Are Poor Metabolizers of Desloratadine (Study P02994)	Completed	Merck Sharp & Dohme Corp.	Phase 3	2002-11-01	This study was conducted to evaluate the safety and tolerance of desloratadine after 5 weeks of repetitive dosing in children ages 2 to 12 years old with allergic hypersensitivity or chronic hives. All of the subjects enrolled in this trial were previously identified in an earlier trial to be poor metabolizers of desloratadine.
NCT00783133 ↗	Preference for Clarinex Tablets vs. Allegra Tablets in Patients With Seasonal Allergies (Study P03177)	Completed	Merck Sharp & Dohme Corp.	Phase 4	2002-11-01	This was a crossover study designed to see if patients with seasonal allergy symptoms preferred Clarinex® or Allegra®. Patients were randomized to take 7 days of Clarinex or Allegra treatment, followed by a 5 to 28-day washout period (days when no drug is given), followed by 7 days of the opposite treatment. At the end of each 7-day treatment, patients were asked questions to determine which drug, Clarinex or Allegra, the patient prefers more.
NCT00794248 ↗	Preference for Clarinex Tablets vs. Allegra Tablets in Patients With Seasonal Allergies (Study P03179)	Completed	Merck Sharp & Dohme Corp.	Phase 4	2002-11-01	This was a crossover study designed to see if patients with seasonal allergy symptoms preferred Clarinex® or Allegra®. Patients were randomized to take 7 days of Clarinex or Allegra treatment, followed by a 5 to 28-day washout period (days when no drug is given), followed by 7 days of the opposite treatment. At the end of each 7-day treatment, patients were asked questions to determine which drug, Clarinex or Allegra, the patient prefers more.
NCT00794495 ↗	Preference for Clarinex Tablets vs. Zyrtec Tablets in Patients With Allergies (P03181)	Completed	Merck Sharp & Dohme Corp.	Phase 4	2002-12-01	This was a crossover study designed to see if patients with allergy symptoms preferred Clarinex® or Zyrtec®. Patients were randomized to take 7 days of Clarinex or Zyrtec treatment, followed by a 5 to 28-day washout period (days when no drug is given), followed by 7 days of the opposite treatment. At the end of each 7-day treatment, patients were asked questions to determine which drug, Clarinex or Zyrtec, the patient prefers more.
NCT00794599 ↗	Preference for Clarinex Tablets vs. Zyrtec Tablets in Patients With Allergies (P03182)	Completed	Merck Sharp & Dohme Corp.	Phase 4	2002-12-01	This was a crossover study designed to see if patients with allergy symptoms preferred Clarinex® or Zyrtec®. Patients were randomized to take 7 days of Clarinex or Zyrtec treatment, followed by a 5 to 28-day washout period (days when no drug is given), followed by 7 days of the opposite treatment. At the end of each 7-day treatment, patients were asked questions to determine which drug, Clarinex or Zyrtec, the patient prefers more.

Clinical Trial Conditions for clarinex d 24 hour

Condition Name

Condition Name for clarinex d 24 hour
Intervention	Trials
Seasonal Allergic Rhinitis	7
Healthy	5
Perennial Allergic Rhinitis	3
Allergic Rhinitis	2

Condition MeSH

Condition MeSH for clarinex d 24 hour
Intervention	Trials
Rhinitis, Allergic	9
Rhinitis	9
Rhinitis, Allergic, Seasonal	7
Rhinitis, Allergic, Perennial	3

Clinical Trial Locations for clarinex d 24 hour

Trials by Country

Trials by Country for clarinex d 24 hour
Location	Trials
United States	8
Canada	2

Trials by US State

Trials by US State for clarinex d 24 hour
Location	Trials
Florida	5
New Jersey	2
Kentucky	1

Clinical Trial Progress for clarinex d 24 hour

Clinical Trial Phase

Clinical Trial Phase for clarinex d 24 hour
Clinical Trial Phase	Trials
Phase 4	9
Phase 3	2
Phase 2	1

Clinical Trial Status

Clinical Trial Status for clarinex d 24 hour
Clinical Trial Phase	Trials
Completed	18
Active, not recruiting	1

Clinical Trial Sponsors for clarinex d 24 hour

Sponsor Name

Sponsor Name for clarinex d 24 hour
Sponsor	Trials
Merck Sharp & Dohme Corp.	9
Dr. Reddy's Laboratories Limited	6
Sanofi	2

Sponsor Type

Sponsor Type for clarinex d 24 hour
Sponsor	Trials
Industry	19
Other	1